If you have been reading about synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-22. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
New revelations were supported by an increase in dinosaur discoveries. Major new dinosaur discoveries have been made by paleontologists working in previously unexplored regions, including India, South America, Madagascar, Antarctica, and most significantly China. Across theropods, sauropodomorphs, and ornithischians, the number of named genera began to increase drastically in the 1990s, with up to 30 new species of dinosaurs named each year by 2008. At least sauropodomorphs experienced a further increase in the number of named species in the 2010s, with an average of 9.3 new species having been named each year between 2009 and 2020. As a consequence, more sauropodomorphs were named between 1990 and 2020 than in all previous years combined. These new localities also led to improvements in overall specimen quality, with new species being increasingly named not on scrappy fossils but on more complete skeletons, sometimes from multiple individuals. Better specimens also led to new species being invalidated less frequently. Asian localities have produced the most complete theropod specimens, while North American localities have produced the most complete sauropodomorph specimens. Prior to the dinosaur renaissance, dinosaurs were mostly classified using the traditional rank-based system of Linnaean taxonomy. The renaissance was also accompanied by the increasingly widespread application of cladistics, a more objective method of classification based on ancestry and shared traits, which has proved tremendously useful in the study of dinosaur systematics and evolution.
=== Paramount and CBS partnership === On August 11, 2025, the UFC announced a seven-year media rights agreement with Paramount Skydance Corporation worth $7.7 billion. Paramount+ will exclusively stream all events for seven years, starting in 2026. Some numbered events will also air on CBS. The agreement will allow the UFC to move away from pay-per-view as events will stream on Paramount+ at no additional cost. All 13 of the UFC's flagship events and 30 Fight Nights a year will be streamed on the Paramount+ service. UFC CEO and President Dana White announced the UFC would produce four big events per year on CBS, and that the UFC's planned card for the White House on June 14th, 2026 would be one of those events.
== Pharmacology == It selectively binds to inflamed tissues (Prostaglandin synthetase inhibitor) and is normally free of adverse systemic effects. Unlike other NSAIDs, it does not inhibit cyclooxygenase or lipooxygenase, and is not ulcerogenic. Benzydamine has been investigated for activity at several ion channels and receptors involved in nociception. In vitro electrophysiological studies have shown that it inhibits voltage-gated sodium channel Nav1.8 currents at micromolar concentrations, while having no action as an agonist or antagonist at TRPA1 or TRPV1 channels, and no significant effect on Kv7.2/7.3 potassium channels. It is described as having powerful reinforcing effects in animals and showing cross-sensitization with drugs of misuse such as heroin and cocaine. It is hypothesized that it has cannabinoid agonistic activity and this may account for its recreational and hallucinogenic effects. However, it has also been theorized that, based on structural similarity to lysergic acid diethylamide (LSD) and descriptions of its visual hallucinatory effects, benzydamine might be acting as a serotonin 5-HT2A receptor agonist and hence as a serotonergic psychedelic. More research is needed to determine the mechanism of action of the effects of benzydamine as a drug of misuse.
Mothers who take certain recreational drugs should not breastfeed, however, most medications are compatible with breastfeeding. Available evidence indicates that it is unlikely that COVID-19 can be transmitted through breast milk. Smoking tobacco and consuming limited amounts of alcohol or coffee are not reasons to avoid breastfeeding.
Sources: en.wikipedia.org
=== American Revolution, the East India Company, and early America context === Thomas Paine was a notable critic who warned Americans against the evils of the British Empire. As Paine prepared and published his highly influential pamphlet Common Sense (January 1776), he was influenced by reports from 1775 on the East India Company's activities and parliamentary investigations in London. These events helped shape his anti-imperial perspective, informing indirect commentary on the imperial ventures in India. He saw the British East India Company's 1757 rise in Bengal as extortionate and foreshadowing what would happen to the United States if it failed to secure its independence. Heavy taxation on Indian commodities imported to the United States, such as high-quality fabrics, also played a role in creating discontent with British rule.
== Prognosis == AMC is considered non-progressive, so with proper medical treatment things can improve. The joint contractures will not get worse than they are at the time of birth. There is no way to resolve or cure AMC completely but with proper treatment most children make significant improvements in their range of motion and ability to move their limbs, which enables them to carry out daily activities and live relatively normal lives. Therapeutic interventions that are cornerstones in the treatment of AMC include: stretching and range of motion exercises, physical, occupational and speech therapy, splinting and serial casting. Surgical intervention may also improve joint mobility and function. Other positive prognostic factors for independent walking are active hips and knees, hip flexion contractures of less than 20 degrees and knee flexion contractures of less than 15 degrees without severe scoliosis.
This is a list of the fastest animals in the world, by types of animal. The peregrine falcon is the fastest bird, and the fastest member of the animal kingdom, with a diving speed of over 300 km/h (190 mph). The fastest land animal is the cheetah, capable of running at speeds of up to 93–104 km/h (58–65 mph). Among the fastest animals in the sea is the black marlin, with uncertain and conflicting reports of recorded speeds. When drawing comparisons between different classes of animals, an alternative unit is sometimes used for organisms: body length per second. On this basis the 'fastest' organism on earth, relative to its body length, is the Southern Californian mite, Paratarsotomus macropalpis, which has a speed of 322 body lengths per second. The equivalent speed for a human, running as fast as this mite, would be 1,300 mph (2,092 km/h), or approximately Mach 1.7. The speed of the P. macropalpis is far in excess of the previous record holder, the Australian tiger beetle Rivacindela eburneola, which is the fastest insect in the world relative to body size, with a recorded speed of 1.86 metres per second (6.7 km/h; 4.2 mph), or 171 body lengths per second. The cheetah, the fastest land mammal, scores at only 16 body lengths per second. Body mass can also be used to compare speed between species on a relative basis. Under this parameter the fastest animal for its body mass is the cheetah, followed by the pronghorn.
Sources: en.wikipedia.org
=== Other === Chest pain may be accompanied by sweating, nausea or vomiting, and fainting, and these symptoms may also occur without any pain at all. Dizziness or lightheadedness is common and occurs due to reduction in oxygen and blood to the brain. In females, the most common symptoms of myocardial infarction include shortness of breath, weakness, and fatigue. Females are more likely to have unusual or unexplained tiredness and nausea or vomiting as symptoms. Females having heart attacks are more likely to have palpitations, back pain, labored breath, vomiting, and left arm pain than males, although the studies showing these differences had high variability. Females are less likely to report chest pain during a heart attack and more likely to report nausea, jaw pain, neck pain, cough, and fatigue, although these findings are inconsistent across studies. Females with heart attacks also had more indigestion, dizziness, loss of appetite, and loss of consciousness. Shortness of breath is a common, and sometimes the only symptom, occurring when damage to the heart limits the output of the left ventricle, with breathlessness arising either from low oxygen in the blood or pulmonary edema. Other less common symptoms include weakness, light-headedness, palpitations, and abnormalities in heart rate or blood pressure. These symptoms are likely induced by a massive surge of catecholamines from the sympathetic nervous system, which occurs in response to pain and, where present, low blood pressure.
== Pathophysiology == When ingested, hypoglycin A is metabolized to produce methylenecyclopropylacetic acid (MCPA). MCPA acts to inhibit the beta-oxidation of fatty acids in two ways. First, it interferes with the transport of long-chain fatty acids into the mitochondria by forming ester linkages with carnitine and coenzyme A (CoA). Also, it inhibits acyl-CoA dehydrogenases, so that only unsaturated fatty acids can be fully oxidized. Fatty acids accumulate in the liver in a microvesicular pattern that can be seen on biopsy. In the absence of fatty acid metabolism, the body becomes dependent on glucose and glycogen for energy. Octreotide can be used to reduce the secretion of insulin by the pancreas, thereby preventing severe hypoglycemia. Inhibition of beta-oxidation of fatty acids, however, also depletes nicotinamide adenine dinucleotide (NADH) and acetyl CoA—the latter an activator of pyruvate carboxylase—inhibiting gluconeogenesis. Once the liver glycogen stores are depleted, the body cannot synthesize glucose, and severe hypoglycemia results. Initial symptoms appear after about four hours, and deaths have been reported from 12 to 48 hours following consumption. Supportive care involves carefully metered IV glucose infusion and fluid/electrolyte replacement; mortality was 80% before glucose infusion was introduced in 1954. A similar outbreak of lethal hypoglycemic encephalopathy has been linked to the consumption of lychee fruit in Muzaffarpur, India.
Another interpretation, using density functional theory calculation, goes as follows: C=C with defects such as functional groups and pentagons (283.6 eV), C=C (non-oxygenated ring contexts) (284.3 eV), sp3C-H in the basal plane and C=C with functional groups (285.0 eV), C=O and C=C with functional groups, C-O (286.5 eV), and O-C=O (288.3 eV). Graphite oxide is hydrophilic and easily hydrated when exposed to water vapor or immersed in liquid water, resulting in a distinct increase of the inter-planar distance (up to 1.2 nm in saturated state). Additional water is also incorporated into the interlayer space due to high pressure induced effects. The maximal hydration state of graphite oxide in liquid water corresponds to insertion of 2-3 water monolayers. Cooling the graphite oxide/H2O samples results in "pseudo-negative thermal expansion" and cooling below the freezing point of water results in de-insertion of one water monolayer and lattice contraction. Complete removal of water from the structure seems difficult since heating at 60–80 °C results in partial decomposition and degradation of the material.
== Acquisitions == In July 2016, Relief acquired FirstString Research, a clinical-stage biotech firm based in Charleston, South Carolina, US. In January 2021, Relief acquired German-based firm AdVita in a €25 million agreement to further their research into inhaled treatments for Acute respiratory distress syndrome. In May 2021, Relief acquired Swiss biotech firm Applied Pharma Research (APR), including its existing portfolio and all pipeline products, for CHF 72 million ($79 million).
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.